journal
MENU ▼
Read by QxMD icon Read
search

Journal of Oncology Pharmacy Practice

journal
https://www.readbyqxmd.com/read/29460706/using-a-treatment-diary-to-improve-the-medication-adherence-in-patients-with-chronic-myeloid-leukaemia
#1
Fiorenzo Santoleri, Ruggero Lasala, Andrea Logreco, Elena Ranucci, Alberto Costantini
Purpose The aim of this study was to verify whether the distribution of a treatment diary by a pharmacist could influence the adherence to oral treatment with imatinib, nilotinib, and dasatinib in patients with chronic myeloid leukaemia. Methods The level of adherence was calculated using the received daily dose/prescribed daily dose ratio and compared between patients who used a diary and those who did not. Results Forty-four (35.8%) of 123 patients with chronic myeloid leukaemia completed the diary: 20 (45...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29460705/a-single-center-retrospective-cohort-study-comparing-low-molecular-weight-heparins-to-direct-oral-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer-a-real-world-experience
#2
Megan K Phelps, Tracy E Wiczer, H Paige Erdeljac, Kelsey R Van Deusen, Kyle Porter, Gary Philips, Tzu-Fei Wang
Introduction Low-molecular-weight heparins are the standard treatment for cancer-associated thrombosis. Recently, direct oral anticoagulants are a new option for thrombosis treatment; however, data supporting the use of direct oral anticoagulants for cancer-associated thrombosis are limited. Objectives The primary objective of this study was to determine the rate of recurrent cancer-associated thrombosis and major bleeding within 6 months of starting either low-molecular-weight heparin or direct oral anticoagulant for treatment of cancer-associated thrombosis...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29460704/current-status-of-drug-vial-optimization-use-to-prevent-waste-associated-with-injectable-anticancer-agents
#3
Shinya Suzuki, Peter Gilbar, Bo Yu, Chihiro Matsuyama, Masakazu Yamaguchi
No abstract text is available yet for this article.
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29460703/practice-insights-on-patient-care-management-overview-for-chemoradiation-toxic-mucositis-guidelines-guideline-supported-therapies-and-high-potency-polymerized-cross-linked-sucralfate-prothelial
#4
Ricky W McCullough
Aim To offer a practice insight for the management of chemoradiation toxic mucositis. Method Review chemoradiation toxic mucositis, its pathobiology and breadth of symptom presentation. Review mucositis guidelines and guideline-supported anti-mucositis therapies. Offer guidance on guidelines and an abbreviated review of high potency cross-linked sucralfate for management of chemoradiation toxic mucositis. Result There are six major mucositis guidelines but only one that is current and regularly updated. Guidelines from the Multinational Association Supportive Cancer Care suggest 14 interventions gleaned from controlled trials, 12 of which are off-label uses of therapies that offer statistically significant but incrementally beneficial outcomes...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29451420/integration-of-clinical-pharmacists-into-an-ambulatory-pediatric-hematology-oncology-transplant-clinic
#5
Kimberly D Defoe, Jennifer Jupp, Tara Leslie
Objectives To describe key activities performed by a newly deployed clinical pharmacist in an outpatient pediatric hematology, oncology, transplant clinic. To demonstrate how utilization of the pharmacist evolved, as indicated by changes in frequency of key activities, during the first four months of integration. Design Clinical pharmacists were made consistently available in an outpatient clinic serving hematology, oncology, transplant patients and their families. A list of key activities, based on provincial clinical pharmacist standards, was created to provide a framework for the role...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29444609/optimization-of-resources-by-drug-management-a-multicentred-web-administered-study-on-the-use-of-ipilimumab-in-italy
#6
V Damuzzo, A Russi, M Chiumente, C Masini, B Rebesco, F Gregis, S Nozza, J Pigozzo, V Chiarion-Sileni, A C Palozzo
Objective In a scenario of new expensive cancer therapies entering the market, strategies of optimisation and cost containment are crucial in oncology care. Better management of drug waste and centralization of drug preparation can be effective strategies to achieve these goals. The aim of this work is to describe the economic management of a high cost anticancer drug (ipilimumab) in some Italian reference centres. Methods This was an observational, multicentred study in which economical and clinical data of 21 cancer centres (418 patients) were collected during the enrollment period from February 2013 to August 2014...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29444608/acute-autoimmune-myocarditis-and-hepatitis-due-to-ipilimumab-monotherapy-for-malignant-melanoma
#7
Yazeed Samara, Chun Lai Yu, Constantin A Dasanu
An important agent in melanoma therapy, ipilimumab is associated with autoimmune toxicity. Two cases of autoimmune pericarditis and large pericardial effusion have been documented with its use. Reports of myocardial toxicity have surfaced with this agent, mainly when used in combination with PD1 blockade. We present herein a case of autoimmune myocarditis leading to biventricular failure after four doses of IV ipilimumab 3 mg/kg as a single agent. Furthermore, this toxic effect may be anticipated with PD1 inhibitors...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29409391/adverse-events-associated-with-aprepitant-pediatric-bone-cancer-patients
#8
Lucas M Okumura, Sacha A da Silva Ries, Clarice F Meneses, Mariana B Michalowski, Maria Angelica P Ferreira, Leila B Moreira
An eight-year long case series follow-up study with pediatric bone cancer patients was conducted to compare the occurrence of adverse events associated with aprepitant with official sources of drug information (manufacturer's leaflet, clinical trials, and European Medicines Agency leaflet). All patients admitted were analyzed, representing 192 aprepitant cycles. Anorexia, febrile neutropenia, and headache were observed in frequencies over 43.8 per 100 patients, which was higher than previous estimates. Adverse events were classified as probable or possible, by using Naranjo score...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29385883/successful-use-of-cytarabine-and-bendamustine-in-a-patient-with-mantle-cell-lymphoma-and-acute-renal-failure-using-intermittent-hemodialysis-a-case-report
#9
Matthew Ettleson, Kale S Bongers, Kaitlyn Vitale, Anthony J Perissinotti, Tycel Phillips, Bernard L Marini
Mantle cell lymphoma is a mature B-cell non-Hodgkin lymphoma characterized by the hallmark (11;14) chromosomal translocation, which often presents with lymphadenopathy and extra-nodal involvement. Young, fit patients are generally treated with chemotherapy approaches that incorporate high-dose cytarabine (e.g. the Nordic regimen) followed by autologous hematopoietic cell transplantation. Because of the significant activity of cytarabine in mantle cell lymphoma, increasingly, high- and intermediate-dose cytarabine are being used in the treatment of elderly mantle cell lymphoma patients...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29385882/cost-utility-analysis-of-trastuzumab-combined-with-docetaxel-for-patients-with-her-2-positive-metastatic-breast-cancer-real-world-claim-data
#10
Henry Wc Leung, Agnes Lf Chan, Shyh-Yau Wang
Objectives To model the cost-utility of trastuzumab combined with docetaxel for patients with HER-2 positive metastatic breast cancer (mBC) without prior other chemotherapy. Methods A Markov cohort simulation was used to model the cost-utility of trastuumab combined with docetaxel (TD) for women with HER-2 positive metastatic breast cancer without prior chemotherapy from the perspective of Taiwan National Health Service (NHS). The clinical and economic data were retrieved directly from the Catastrophic Illness Patient Databases (CIPD)...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29375015/how-can-the-use-of-closed-system-transfer-devices-to-facilitate-sharing-of-drug-vials-be-optimised-to-achieve-maximum-cost-savings
#11
Peter J Gilbar, Carole R Chambers, Johan Vandenbrouche, Paul Jm Sessink, Timothy G Tyler
No abstract text is available yet for this article.
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29375014/impact-of-a-formal-pharmacist-run-oral-antineoplastic-monitoring-program-a-pilot-study-in-an-adult-genitourinary-oncology-clinic
#12
Brette Conliffe, Lindsay Figg, Padmini Moffett, Leslie Lauterwasser, Laura Beth Parsons
Background In recent years, there has been a changing paradigm in the management of oncologic disease states from the use of intravenous therapies, requiring a visit to the infusion center or hospitalization, to new therapies that can be administered orally.1,2 Several publications have evaluated the role pharmacists may play in the initial prescribing of oral chemotherapy, however the impact of a formalized pharmacist follow-up program has not been well defined. This study evaluates the impact of a pilot pharmacist-run oral antineoplastic monitoring program...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29357782/aplastic-anemia-secondary-to-propylthiouracil-a-rare-and-life-threatening-adverse-effect
#13
Hira Shaikh, Amir Kamran, Soorih Shaikh, Prerna Mewawalla
Background Propylthiouracil has been in use for more than half a century for the treatment of hyperthyroidism. While it is largely known to cause agranulocytosis, its association with aplastic anemia is rarely heard of. Our case will be the third in literature to suggest aplastic anemia as a manifestation of propylthiouracil, which unfortunately culminated in the death of the patient. Case A 67-year-old female, with recently diagnosed metastatic adenocarcinoma of the lung, developed hyperthyroidism after being started on Nivolumab and Iplimumab...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29357781/dynamic-dosing-of-romiplostim-in-patients-with-immune-thrombocytopenia-purpura-two-case-reports
#14
Jeffrey A Gilreath, Mei Wei, Shilpa Paul, Charles J Parker, David D Stenehjem, George M Rodgers
Romiplostim is a thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia purpura. When following FDA-approved romiplostim prescribing recommendations to withhold treatment for platelet counts above 400k/µL, some patients exhibit a precipitous decline in their platelet count potentially causing patient harm. We present two cases where stable platelet counts were achieved only through persistent weekly dosing of romiplostim despite platelet counts above 400k/µL on the day of administration...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29357780/crizotinib-induced-erosive-esophagitis-in-a-pediatric-patient-with-neuroblastoma
#15
Nicole Lubcke, Kevin Van Camp
Crizotinib is an oral tyrosine kinase inhibitor, approved by the FDA in 2011, for use in anaplastic lymphoma kinase positive, metastatic, non-small cell lung cancer. Crizotinib inhibits oncogenic protein expression and impairs cellular proliferation in tumors with an overexpressed anaplastic lymphoma kinase gene. Currently used most frequently in the adult patient population, pediatric use is becoming more prominent, specifically in disease states exhibiting anaplastic lymphoma kinase-positive, metastatic disease, such as neuroblastoma...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29343154/dasatinib-induced-pulmonary-arterial-hypertension-a-rare-late-complication
#16
Uroosa Ibrahim, Amina Saqib, Vidhya Dhar, Marcel Odaimi
Dasatinib is a dual Src/Abl tyrosine kinase inhibitor approved for frontline and second line treatment of chronic phase chronic myelogenous leukemia. Pulmonary arterial hypertension is defined by an increase in mean pulmonary arterial pressure >25 mmHg at rest. Dasatinib-induced pulmonary hypertension has been reported in less than 1% of patients on chronic dasatinib treatment for chronic myelogenous leukemia. The pulmonary arterial hypertension from dasatinib may be categorized as either group 1 (drug-induced) or group 5 based on various mechanisms that may be involved including the pathogenesis of the disease process of chronic myelogenous leukemia...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29343153/cryptococcal-infections-in-two-patients-receiving-ibrutinib-therapy-for-chronic-lymphocytic-leukemia
#17
Matthew Stankowicz, Megan Banaszynski, Russell Crawford
Cryptococcal infections are responsible for significant morbidity and mortality in immunocompromised patients. Reports of these infections in patients on small molecular kinase inhibitors have not been widely reported in clinical trials. We describe one case of cryptococcal meningoencephalitis and one case of cryptococcal pneumonia in two patients who were receiving ibrutinib for chronic lymphocytic leukemia. Despite different sites of cryptococcal infection, both patients had similar presentations of acute illness...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29343152/impact-of-dosage-timing-on-the-bioavailability-of-oral-anticancer-medications-is-pre-prandial-dosing-equivalent-to-post-prandial-dosing
#18
Guo Yu, Dan-Na Wu, Yichao Yu, Guo-Fu Li, Hong-Hao Zhou
Many oral anticancer agents are recommended to be given either at least 1 h before or 2 h after a meal, according to the prescribing information. However, the effect of dosage timing of an oral anticancer agent with reference to food intake on anticancer treatment remains unclear. As shown by the literature survey and labeling analysis for oral anticancer drugs approved by the US Food and Drug Administration from 2010 to 2016, labeling information regarding dosage timing for several anticancer drugs appeared not be optimum, leading to suboptimal bioavailability and plasma drug concentrations...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29338572/implementation-of-additional-prescribing-authorization-among-oncology-pharmacists-in-alberta
#19
Bianca Au, Deonne Dersch-Mills, Sunita Ghosh, Jennifer Jupp, Carole Chambers, Frances Cusano, Melanie Danilak
Purpose To describe the practice settings and prescribing practices of oncology pharmacists with additional prescribing authorization. Methods A descriptive, cross-sectional survey of all oncology pharmacists in Alberta was conducted using a web-based questionnaire over four weeks between March and April 2016. Pharmacists were identified from the Cancer Services Pharmacy Directory and leadership staff in Alberta Health Services. Descriptive statistics were used to describe the practice setting, prescribing practices, motivators to apply for additional prescribing authorization, and the facilitators and barriers of prescribing...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29334337/durable-responses-in-refractory-autoimmune-hemolytic-anemia-with-alemtuzumab
#20
Renee K McAlister, Mahsa S Talbott, Nishitha M Reddy
Autoimmune hemolytic anemia occurs due to an interaction of IgG antibodies with protein antigens expressed on red blood corpuscles. Glucocorticoids are the mainstay of treatment for autoimmune hemolytic anemia. For patients not responding to initial therapy, other agents such as rituximab, immunosuppressive therapy, or splenectomy are considered. When refractory to these treatment options, alemtuzumab is an alternative agent. However, long-term outcomes of patients supporting its use are lacking. We present three patients with refractory autoimmune hemolytic anemia treated with alemtuzumab...
January 1, 2018: Journal of Oncology Pharmacy Practice
journal
journal
32324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"